---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020039"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:22:50.626378+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alumis and ACELYRIN reaffirm all-stock merger; pro forma cash ~$737M

## Summary
- Alumis and ACELYRIN reaffirm commitment to merge in an all-stock transaction expected to close Q2 2025.
- Pro forma cash of ~$737M as of Dec 31, 2024 provides runway into 2027.
- Alumis had ~$289M cash, ACELYRIN ~$448M (preliminary, each as of Dec 31, 2024).
- Combined portfolio includes ESK-001 (psoriasis, lupus), lonigutamab (thyroid eye disease), A-005 (multiple sclerosis).
- Transaction subject to stockholder approvals and customary closing conditions.

## SEC filing metadata
- accession: 0001104659-25-020039
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465925020039/0001104659-25-020039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465925020039/tm258190d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020039
- JSON: https://secwatch.observer/filing/0001104659-25-020039.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.